We then evaluated the effect of VX-770 (ivacaftor), a therapeutic potentiator used to improve the function of the G551D-CFTR channel activity by increasing its open state probability [15] with clinical benefit for CF patients [32]. Here, CFTR is linked to cystic fibrosis.